Recursion Pharmaceuticals (RXRX) director sale under Rule 10b5-1 plan

Rhea-AI Filing Summary

Recursion Pharmaceuticals director Blake Borgeson reported selling 220,000 shares of the company’s Class A common stock on January 6, 2026 at a price of $4.36 per share. After this transaction, he beneficially owned 6,649,863 shares of Class A common stock in direct ownership.

The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that Borgeson adopted on August 31, 2025. Such plans are designed to allow insiders to sell shares according to a preset schedule or conditions, helping separate routine liquidity transactions from day-to-day market or company developments.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Borgeson Blake

(Last) (First) (Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UT 84101

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	01/06/2026		S(1)		220,000	D	$4.36	6,649,863	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025.

Remarks:

	/s/ Jonathan Golightly, attorney-in-fact	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Recursion Pharmaceuticals (RXRX) report for Blake Borgeson?

Recursion Pharmaceuticals reported that director Blake Borgeson sold 220,000 shares of Class A common stock on January 6, 2026 in a Form 4 filing.

At what price were the RXRX shares sold by director Blake Borgeson?

Borgeson’s sale of Recursion Pharmaceuticals Class A common stock was reported at a price of $4.36 per share.

How many Recursion Pharmaceuticals shares does Blake Borgeson own after this transaction?

Following the reported sale, Blake Borgeson beneficially owned 6,649,863 shares of Recursion Pharmaceuticals Class A common stock in direct ownership.

Was the Blake Borgeson RXRX share sale under a Rule 10b5-1 plan?

Yes. The filing states that this transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by Borgeson on August 31, 2025.

What is the role of Blake Borgeson at Recursion Pharmaceuticals (RXRX)?

According to the filing, Blake Borgeson is a director of Recursion Pharmaceuticals and is not listed as an officer or 10% owner.

Is Blake Borgeson’s ownership in RXRX direct or indirect after the sale?

The Form 4 indicates that Borgeson’s 6,649,863 shares are held with direct (D) ownership, with no nature of indirect ownership specified.